In patients with systolic blood pressure of 180 mmhg or more andor diastolic blood pressure of 110 mmhg or more, the risks of bleeding with tenecteplase therapy are increased and should be. The protocol is only to be used in facilities that have fully implemented the nat protocol and when there is no medical officer on site at the time of presentation. Tenecteplase sold under the trade names tnkase and metalyse is an enzyme used as a thrombolytic drug tenecteplase is a tissue plasminogen activator tpa produced by recombinant dna technology using an established mammalian cell line chinese hamster ovary cells. Patient deaths have been reported when healthcare providers confused tpa and tnk. Tenecteplase utility in acute ischemic stroke patients the american.
The overall benefit from alteplase is substantial, but some evidence indicates that alteplase also has negative effects on the ischaemic brain. The assessment of the safety and efficacy of a new treatment strategy with. The american heart association and the american stroke association released several clarifications, updates, andor modifications to the 2018 guidelines for the early management of patients with acute ischemic stroke on april 18, 2018. Prior to 2017, six small clinical studies of tenecteplase in acute stroke had been reported 27,30 32 including three small rcts. A pilot doseescalation safety study of tenecteplase in acute. In the presence of fibrin, in vitro studies demonstrate that tenecteplase conversion of plasminogen to plasmin is increased relative to its conversion in the absence of fibrin. Although guidelines for the medical treatment of ami are available, management by cardiologists and emergency physicians varies greatly throughout the world. In most countries, alteplase given within 45 h of onset is the only approved medical treatment for acute ischaemic stroke. Alteplase is the only approved thrombolytic agent for acute ischaemic stroke. It also is used to treat patients before endovascular thrombectomy, although this recommendation remains controversial.
Tenecteplase is contraindicated in patients with severe uncontrolled hypertension. Tenecteplase in wakeup ischaemic stroke trial twist the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Study protocol open access the norwegian tenecteplase stroke trial nortest. Dec 24, 2019 tenecteplase is a modified form of human tissue plasminogen activator tpa that binds to fibrin and converts plasminogen to plasmin. St elevation myocardial infarction with onset of symptoms 15 minutes and 1 mm in chest or the limb leads or 2mm in men 1.
Tenecteplase in stroke patients between 4 and 24 hours. Tenecteplase is a 527 amino acid glycoprotein developed by introducing the following modifications to the complementary dna cdna for natural human tpa. However, its efficacy and safety in acute ischemic strokes are limited. This study will evaluate the efficacy and safety of tenecteplase compared with placebo in patients with acute ischemic stroke ais. Our emergency department has within it an emergency intensive care unit. Acute ischemic stroke thrombolysis with tenecteplase. Currently, 2018 ahaasa acute ischemic stroke treatment guidelines designate tnk as an alternative to tpa and recommend dose of 0. Tenecteplase is a genetically mutated variant of alteplase with superior pharmacodynamic and pharmacokinetic properties. Please see full prescribing information for additional important safety information. Respecting these limitations, a matched comparative study of alteplase versus tenecteplase in acute ischemic stroke is underway at our hospital. The nat protocol is only for the management of patients with stemi confirmed by the ecg reading service and who meet all nat criteria. This trial showed better shortterm radiologic and clinical outcomes with tenecteplase than with tpa for acute ischemic stroke. Patients who cannot undergo primary pci within one hour as recommended by guidelines and receive. It is recommended that each stroke unit and country stroke services use this document to generate a hospital specific management protocol that is ratified by their respective protocol committee.
A randomisedcontrolled trial of thrombolytic treatment with tenecteplase for acute ischaemic. Tenecteplase is a 527 amino acid glycoprotein developed by introducing the. Mortality, stroke, and combined outcome of death or stroke. Tenecteplase is a 527 amino acid glycoprotein developed by. Further, we performed iv thrombolysis with tenecteplase within 3 h of the symptoms onset, however, the benefits need to be confirmed in the extended time window of 4. What are some things i need to know or do while i take tenecteplase. Tenecteplase tnkase a d d r e s s o g r a p h treatment regimen. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. Tenecteplase versus alteplase for management of acute. The terminal phase halflife of tenecteplase was 90 to minutes. Prescribing and administration guide for intraarterial.
Study protocol open access the norwegian tenecteplase. Tenecteplase not better or safer in ischemic stroke medpage. Mar 09, 2018 tnkase tenecteplase is supplied as a sterile, lyophilized powder in a 50 mg vial under partial vacuum. The newer thrombolytic drug tenecteplase has been investigated in one randomised trial up to 3 h after stroke and in another trial up to 6 h after stroke. Jan 01, 2020 tnkase is a sterile, white to offwhite, lyophilized powder for single intravenous iv bolus administration after reconstitution with sterile water for injection swfi, usp.
Also available are the national stroke services frameworks, which support the clinical guidelines by guiding service planning, monitoring and improvement of appropriate acute and rehabilitation stroke services. Nurse administered thrombolysis nat protocol for st. Tenecteplase sold under the trade names tnkase and metalyse is an enzyme used as a thrombolytic drug. Tenecteplase in wakeup ischaemic stroke trial full text. Tenecteplase, a genetically engineered mutant tissue plasminogen activator, is an alternative thrombolytic agent. Unlike alteplase, tenecteplase is available as a single bolus dose. However, neither tenecteplase nor reteplase is approved for ais treatment. A randomized trial of tenecteplase versus alteplase for. The median age of participants was 77 years iqr 6479 and the median national institutes of health stroke scale score at baseline was 4 points iqr 28.
Stroke management procedures and protocols clinical guideline. Summary tenecteplase in wakeup ischaemic stroke trial twist is a randomisedcontrolled, openlabel trial of thrombolytic treatment with tenecteplase for acute ischaemic stroke upon awakening. Protocol tenecteplase in wakeup ischaemic stroke trial twist. Reperfusion therapy for acute myocardial infarction. Most patients enrolled in this study had mild stroke. The extendia tnk trial suggesting better outcomes with tenecteplase than alteplase in the treatment of acute ischemic stroke has now been published in the new england journal of medicine. Listing a study does not mean it has been evaluated by the u. We conducted the tenecteplase versus alteplase before endovascular therapy for ischemic stroke extendia tnk trial to com pare tenecteplase with alteplase in establishing reperfusion in patients before endovascular. Each 50 mg vial of tnkase is packaged with one 10 ml vial of sterile water for injection, usp for reconstitution, the bd 10 ml syringe with twinpak dual cannula device, and three alcohol prep pads. Thrombolysis with tenecteplase is as safe as alteplase in. You must check to make sure that it is safe for you to take tenecteplase with all of your drugs and health problems. Acute myocardial infarction preprinted order sheet.
The qas would welcome notification from any holder who has been omitted or incorrectly acknowledged. Should serious bleeding occur, concomitant heparin and antiplatelet therapy should be discontinued. Review of tenecteplase tnkase in the treatment of acute. The study protocol of attest has been detailed elsewhere.
Protocol tenecteplase in wakeup ischaemic stroke trial. Tenecteplase is an enzyme that, when present in blood in pharmacologic concentrations, remains active under in vitro conditions. For tnkase treated patients in assent2, the incidence of intracranial hemorrhage was 0. One when tenecteplase was prescribed and administered but the dose used was the alteplase dose because of confusion over the abbreviation tpa and use of another hospitals protocol. Tenecteplase has entered stroke guidelines as an alternative to alteplase 1,18,19 and is supported by a metaanalysis indicating noninferiority of tenecteplase vs alteplase. Alteplase has been the mainstay of thrombolytic treatment since the national institutes of neurological disorders and stroke trial was published.
Do not start, stop, or change the dose of any drug without checking with your doctor. Guidelines for stroke management 2017, stroke foundation sf and its 2018 endovascular thrombectomy evt focused update. Tnkase tenecteplase dose, indications, adverse effects. Food and drug administration for use in mortality reduction associated with acute myocardial infarction ami.
Tenecteplase for the treatment of acute ischemic stroke. Tenecteplase is a thrombolytic thrombolitik drug, sometimes called a clotbusting drug. Tenecteplase utility in acute ischemic stroke patients. Tnkase tenecteplase description tnkase tenecteplase is a tissue plasminogen activator tpa produced by recombinant dna technology using an established mammalian cell line chinese hamster ovary cells. To our knowledge, this study is the first substantial headtohead comparison of the 2. The safety of tnkase in stemi was investigated in assent1. Tenecteplase versus alteplase before thrombectomy for. Tenecteplase superior to alteplase for stroke lysis medpage. Tnkase fda prescribing information, side effects and uses.
Tenecteplase demonstrated similar safety outcomes as alteplase for thrombolysis in patients with stroke mimics sms, according to the results of a retrospective analysis of a phase 3 trial. Pdf intravenous tenecteplase in acute ischemic stroke. Evidence that tenecteplase is noninferior to alteplase for acute ischemic stroke. Hence, we conducted a study to evaluate the efficacy and safety of tenecteplase compared with alteplase in acute ischemic stroke. All patients will receive standardofcare therapy according to american heart association american stroke association clinical guidelines 2018. Tenecteplase while the qas has attempted to contact all owners, this has not always been possible. The following key points to remember are not impacted by these changes. Pdf the norwegian tenecteplase stroke trial nortest. May 19, 2015 we report our experience in thrombolysis for acute ischemic stroke in patients all treated with tenecteplase metalyse, they were all registred at the emergency department of the mohammed v military hospital of instruction, which is a tertiary hospital in rabat. The clinical guidelines can be found on the informme website, the stroke foundations dedicated website for health professionals. Tenecteplase versus alteplase in stroke thrombolysis.
Tenecteplase was not superior to alteplase and showed a similar safety profile. Tenecteplase, which is more fibrinspecific and has longer activ. Follow these suggestions to prevent any further mishaps. Learn more about singlebolus tnkase tenecteplase acute myocardial infarction treatment and the 5second tnkase dosing and administration. Tenecteplase is a tissue plasminogen activator tpa produced by recombinant dna technology using an established mammalian cell line chinese hamster ovary cells. Food and drug administration has received reports of accidental. Prescribing and administration guide for intraarterial tenecteplase for the treatment of acute limb ischemia background acute limb ischemia ali, defined as any sudden decrease in, or worsening of limb perfusion causing a. There are many guidelines for the treatment of this condition, but they differ in many aspects and even contradict each other in some respects. Tenecteplase tnk is a biogenetic variant of wildtype rtpa that may be given as a single bolus injection. In 99 of 104 patients treated with tenecteplase, mean plasma clearance ranged from 99 to 119 mlmin. Learn more about tnkase tenecteplase administration, and tnkase dosing and reconstitution for acute myocardial infarction treatment.
Tenecteplase was cleared from the plasma with an initial halflife of 20 to 24 minutes. Stroke management procedures and protocols sa health. Asa 320 mg 4 tabs 80 mg chewed stat unless allergic then ecasa 80 mg qd. Tell all of your health care providers that you take tenecteplase. Coagulation and fibrinolytic activity of tenecteplase.
Abstract background intravenous infusion of alteplase is used for thrombolysis before endovascular thrombectomy for ischemic stroke. Tenecteplase is a 527 amino acid glycoprotein developed by introducing the following. The nat protocol authorises a registered nurse rn, who has successfully completed the requisite nat education and accreditation package, to assess the suitability of patients to receive nat which includes the administration of aspirin if not already given clopidogrel, tenecteplase, and enoxaparin, using approved standing orders. Further trials are needed to establish the safety and efficacy in patients with severe stroke and whether tenecteplase is noninferior to alteplase. Because of its rapid singlebolus administration, its use is favored over alteplase in the treatment of acute myocardial infarction. Tenecteplase may be more effective and less harmfull than alteplase, but large randomised controlled phase 3 trials are lacking.
Tenecteplase in wakeup ischaemic stroke trial twist. Approach to reperfusion therapy for acute ischemic stroke uptodate. The newer thrombolytic drug tenecteplase has been investigated in one randomised trial up to 3 h after stroke and in another trial up to 6 h after stroke in patients selected by advanced neuroimaging. The trial was not powered to assess 3month outcomes, but the higherdose tenecteplase patients had better 3month outcomes than the tpa patients. Results systematic search identified 5 trials enrolling 1585 patients 828 tnk, 757 alt. Nov 11, 2005 study of tenecteplase tnk in acute ischemic stroke tnk s2b the safety and scientific validity of this study is the responsibility of the study sponsor and investigators.
Tenecteplase versus alteplase for stroke thrombolysis. A final diagnosis other than ischaemic stroke or transient ischaemic attack was found in 99 18% patients in the tenecteplase group and 91 17% patients in the alteplase group. Tnkase tenecteplase is a tissue plasminogen activator tpa produced by recombinant. The mean age of the presentation in tenecteplase group was 66. Aug 03, 2017 cardiology strokes tenecteplase not better or safer in ischemic stroke first headtohead trial shows no advantage against alteplase. Thrombolysis for acute ischemic stroke by tenecteplase in the. Tell your doctor and pharmacist about all of your drugs prescription or otc, natural products, vitamins and health problems. Death or permanent disability can occur in patients who experience stroke or serious bleeding episodes. Any known history of haemorrhagic stroke or stroke of unknown originknown history of ischaemic stroke or transient ischaemic attack in the preceding 6 months. Alteplase versus tenecteplase for thrombolysis after. Study protocol open access the norwegian tenecteplase stroke.
Effect of intravenous tenecteplase dose on cerebral. The initial volume of distribution is weight related and approximates plasma volume. Primary clinical efficacy outcome was defined as an improvement in the national institute of health stroke scale nihss score of. Intravenous alteplase is the only approved treatment for acute ischemic stroke. Study of tenecteplase tnk in acute ischemic stroke tnks2b. Fibrinolytic checklist for stemi heart rate 100min and systolic bp 180 to 200 mm hg or diastolic bp 100 to 110 mm hg right vs left arm systolic bp difference 15 mm hg history of structural central nervous system disease stroke 3 hours or stroke fourth edition, 2009. Protocol this trial protocol has been provided by the authors to give readers additional information about their work. Evidence that tenecteplase is noninferior to alteplase for. It helps your body produce a substance that dissolves unwanted blood clots tenecteplase is used to prevent death in people who have had a heart attack acute myocardial infarction tenecteplase may also be used for purposes not listed in this medication guide. Tnkase tenecteplase is a singlebolus thrombolytic, or clotbusting agent, approved by the u. Tenecteplase has shown a better thrombolytic profile and. The ongoing twist tenecteplase in wakeup ischaemic stroke trial will answer the question of whether tenecteplase is superior to best standard treatment in ischemic stroke for patients in the extended time window unique identifier. One when tenecteplase was administered when alteplase was prescribed. Treatment should be initiated as soon as possible after the onset of ami symptoms.
During tnkase therapy, results of coagulation tests andor measures of fibrinolytic activity may be unreliable unless specific precautions are taken to prevent in vitro artifacts. This is not a list of all drugs or health problems that interact with tenecteplase. Alteplase tpa is the mainstay of treatment for acute ischemic stroke, provided that treatment is initiated within 4. Tenecteplase versus alteplase for stroke thrombolysis evaluation taste, conceived and led by associate professor parsons, is a large phase iii randomised trial designed to generate practicechanging evidence by applying the advanced imaging treatment selection approach used in his recent positive phase ii trial. Jun 08, 2017 tenecteplase in wakeup ischaemic stroke trial twist the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Intravenous thrombolysis with alteplase is the sole approved treatment for eligible patients with acute ischemic stroke.
196 207 369 1389 132 1438 183 924 129 375 673 1635 361 160 1047 1631 496 55 1117 1339 213 169 1177 1112 1565 678 579 1573 361 172 894 210 323 915 1001 1494 548 145 1078